Animal Cell Therapies, Inc., (ACT) a company founded by Dr. Kathy Petrucci, announced a $1.5 million commitment to develop a proprietary line of canine orthopedic products called PROTECT. Animal Cell Therapies, Inc., identifies itself as a veterinary regenerative therapies company.
According to the company, their goal is to increase treatment effectiveness, decrease cost, reduce pain, and be efficiently performed in an outpatient setting. This new specialty line of regenerative medicine products is being developed with the assistance of top researchers at leading institutions, according to a company press release.
“This type of financial commitment demonstrates that we are dedicated to propelling innovation and providing solutions for veterinarians, pets and pet owners,” reported Dr. Kathy Petrucci, Chief Medical Officer of Animal Cell Therapies.
Founded in 2009, ACT is a California-based stem cell research and development facility. The funds for this latest project will enable the company to work with researchers in fully developing the PROTECT Cell Therapy product portfolio.
“We believe R&D capital allocated to strategic partnerships is a necessary step towards commercialization.” said Adam Irving, Chief Executive Officer of Animal Cell Therapies.
In June of 2012, ACT announced the appointment of Leo T. Furcht, M.D. to its Board of Directors. Furcht has published over 175 scientific papers and developed over 30 patents in addition to founding a number of companies.
When the company was created, they partnered with select group of researchers, scientists and collaborators from the U.S. and abroad to create an in-house program to grow and expand well-characterized animal stem cells in a scientific setting.
For more information about ACT, visit http://www.actcells.com.